FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents - Trial NCT02055586
Access comprehensive clinical trial information for NCT02055586 through Pure Global AI's free database. This phase not specified trial is sponsored by Case Comprehensive Cancer Center and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Case Comprehensive Cancer Center
Timeline & Enrollment
N/A
Oct 22, 2013
Dec 27, 2017
Primary Outcome
Concordance analysis of standardized uptake values (SUVs) between the 2 baseline scans,Comparative Analysis of PET/MRI Images
Summary
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission
 tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with
 metastatic solid tumors receiving treatment that blocks blood flow to the tumor. Diagnostic
 procedures, such as FLT-PET/MRI, may help measure a patient's response earlier during
 treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02055586
Non-Device Trial